Author: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, February 2015.
What is systemic lupus erythematosus?
Lupus erythematosus (LE) is a group of diverse, persistent autoimmune inflammatory diseases.
Systemic lupus erythematosus (SLE) affects several organs (such as skin, joints and kidneys) and blood tests reveal circulating autoantibodies. The clinical features of SLE are highly variable and may overlap with other diseases and conditions. Skin involvement or cutaneous lupus (CLE) affects 80% of patients with SLE.
SLE is sometimes called acute lupus erythematosus, and the cutaneous features may be described as acute cutaneous lupus.
Factors leading to SLE include:
The manifestations of SLE are due to loss of regulation of the patient's immune system.
SLE can affect males and females of any age. Every year about 2–7 new cases are diagnosed in a population of 100,000 people. SLE is much more common in females than males, and onset is most often between the ages of 15 and 45 years.
Autoantibodies can be present in people that have no manifestation of the disease.
About 80% of patients with SLE have skin involvement (cutaneous LE), and it is the first sign of SLE in about one-quarter of them. It can present as LE-specific or LE-nonspecific manifestations. LE-specific lesions tend to be induced or aggravated by exposure to ultraviolet radiation and are localised in sun-exposed sites such as the face, neck, V of the neck and upper back.
Cutaneous lupus (CLE) has specific acute, subacute and chronic manifestations.
Nonspecific cutaneous SLE refers to features relating to underlying illness rather than an autoimmune attack. These features may occur in other autoimmune or connective tissue diseases.
Numerous systemic features may occur in SLE and can result in critical illness.
SLE can be difficult to diagnose at times because of the great variety of presentations of the disease, and the presence of similar symptoms in people that do not have the disease. Several attempts have been made to help clinicians reach the diagnosis, including the American College of Rheumatology criteria for the classification of SLE (revised in 1997). In 2012, the criteria were revised by the Systemic Lupus International Collaborating Clinics (SLICC).
Using the SLICC criteria, SLE is diagnosed if the patient has either of the following over time:
These criteria depend on history, clinical examination, exclusion of other causes of the symptoms, and the results of investigations—including blood tests and biopsy of affected tissue. Four of the 17 SLICC criteria relate to the skin.
* SLICC Systemic Lupus International Collaborating Clinics; ANA antinuclear antibody; anti-dsDNA anti–double-stranded DNA
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) was developed in an attempt to classify the severity of CLE.  A score of activity and damage due to the disease is calculated in each of 12 anatomical locations (refer to original published paper for details).
Total activity score is made up of:
Total damage score is made up of:
Patients with SLE often undergo skin biopsy.
Multiple autoantibodies are typically present in SLE, often in high titre (see immunological criteria above). Relating to skin disease in SLE:
Patients with SLE should also have renal, liver and thyroid function and markers of inflammation performed, such as C-reactive protein (CRP), immunoglobulins and rheumatoid factor.
Photoprovocation tests are sometimes carried out to confirm that a skin eruption is precipitated by exposure to particular wavelengths of ultraviolet or visible radiation.
Other tests depend on which organ is affected. They may, for example, include:
The following measures are important to reduce the chance of flares and organ damage.
Intermittent courses of potent topical corticosteroids are important in the treatment of CLE. They should be applied accurately to the skin lesions.
Treatment of SLE depends on which are the predominant organs involved in the disease. Typically, any of the following drugs may be used alone or in combination.
CLE is also sometimes treated with:
SLE leads to a chronic illness with flares and periods of remissions. In some patients, all signs of active disease resolve in time.
See the DermNet NZ bookstore.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.